Chinese Drug Makers Are Doing $60 Billion of Outbound Licensing Deals With Western Pharma This Year, and the US Biosecure Act Has Not Slowed Them
Chinese biotechnology firms signed 53 outbound innovative-drug licensing deals in the first quarter of 2026 alone, with combined deal values exceeding $60 billion and $3.3 billion in upfront cash, and Chinese-origin assets
Follow